Decisions abound now dulaglutide is funded for people with type 2 diabetes

1. Goldenberg RM, Ahooja V, Clemens KK, et al. Practical considerations and rationale for glucagon-like peptide-1 receptor agonist plus sodium-dependent glucose cotransporter-2 inhibitor combination therapy in type 2 diabetes. Can J Diabetes 2021;45(3):291–302.

2. Jabbour SA, Frías JP, Ahmed A, et al. Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION-8 study: A multicenter, double-blind, phase 3, randomized controlled trial. Diabetes Care 2020;43(10):2528–36.

3. Arnott C, Neuen BL, Heerspink HJL, et al. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. Int J Cardiol 2020;318:126–29.

4. Díaz-Trastoy O, Villar-Taibo R, Sifontes-Dubón M, et al. GLP1 receptor agonist and SGLT2 inhibitor combination: An effective approach in real-world clinical practice. Clin Ther 2020;42(2):e1–12.

5. Guo M, Gu J, Teng F, et al. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis. Endocrine 2020;67(2):294–304.

6. Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356–67.

7. Ludvik B, Frías JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2018;6(5):370–81.